SCHEMBL4340944

SCHEMBL4340944

CSCCNC(=O)c1ccc2[nH]nc(-c3cccc(F)c3)c2c1F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 7/20 0.38
MAP2K4 P45985 1/20 0.38
CDK4 P11802 1/20 0.38
CCND1 P24385 1/20 0.38
NTRK1 P04629 1/20 0.38
ABL1 P00519 2/20 0.37
BCR P11274 2/20 0.37
GSK3B P49841 1/20 0.37
WNT1 P04628 4/20 0.36
MAP4K4 O95819 1/20 0.36
GRK6 P43250 1/20 0.36
JAK2 O60674 1/20 0.36
JAK3 P52333 1/20 0.36
TP53 P04637 1/20 0.36
MAPK1 P28482 1/20 0.35
CLK2 P49760 1/20 0.35
CLK3 P49761 1/20 0.35
KDR P35968 1/20 0.35
AURKA O14965 1/20 0.35
AURKB Q96GD4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4334940 0.88 MAP4K4 (0.48) DYRK1AMAP2K4CDK4CCND1NTRK1
SCHEMBL4340999 0.86 WNT1 (0.51) DYRK1AWNT1MAPK1
SCHEMBL4339198 0.85 MAPK1 (0.47) DYRK1AMAP2K4CDK4CCND1NTRK1
SCHEMBL4336321 0.83 MAPK1 (0.43) DYRK1AMAP2K4CDK4CCND1NTRK1
SCHEMBL4346817 0.81 TAAR1 (0.49) CDK4CCND1MAPK1
SCHEMBL4331947 0.80 NAMPT (0.45) CDK4CCND1JAK2JAK3TP53
SCHEMBL2866826 0.80 DYRK1A (0.52) DYRK1AMAP2K4GSK3BWNT1MAP4K4
SCHEMBL27536113 0.79 MAP2K4 (0.47) DYRK1AMAP2K4NTRK1GSK3BJAK2
SCHEMBL4341000 0.79 NPC1 (0.51)
SCHEMBL2864882 0.79 TP53 (0.53) TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
EP-1380576-B1 1H-INDAZOLE COMPOUNDS INHIBITING JNK EISAI R&D MAN CO LTD (JP) 2009-11-25 EP disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-7541376-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-02 US disclosed
US-20050282880-A1 Novel 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203691-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 DYRK1A 1216/4885MAP2K4 61/4885CDK4 103/4885
US-20050282880-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 DYRK1A 1216/4885MAP2K4 61/4885CDK4 103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.